Skip to main content
Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
PostersScientific Publications

Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Date : 10/04/2024

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club